Loading
A phase 1/2 trial of FPI-2265, Actinium-225 PSMA agents, Palacaparib in prostate cancer, run by AstraZeneca, now recruiting.
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07590934 by AstraZeneca, with 152 participants planned, started 2026-06-03 and due to reach its primary completion in 2029-09-25. Interventions recorded: AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent). Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Palacaparib, AstraZeneca, Prostate cancer.
Shares FPI-2265, AstraZeneca, Prostate cancer.
Shares FPI-2265, AstraZeneca, Prostate cancer.
Shares FPI-2265, AstraZeneca, Prostate cancer.
Shares Palacaparib, AstraZeneca.
Shares Actinium-225 PSMA agents, AstraZeneca, Prostate cancer.
Shares Docetaxel, AstraZeneca, Prostate cancer.
Shares Palacaparib, AstraZeneca.